{"description":"All Cause mortality reported for all randomized participants. Serious and other AEs: The full analysis set includes all enrolled participants who received at least 1 infusion.","eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":127,"description":"Participants received 80 milligrams per meter square (mg/m\\^2) golimumab as an intravenous (IV) infusion at Weeks 0, 4, and then every 8 weeks (q8w) till Week 52. Participants also received commercial methotrexate (MTX) weekly through Week 28 at the same body surface area (BSA)-based dosage (10 to 30 mg/m\\^2 per week for participants with BSA less than \\[\\<\\] 1.67 meter square \\[m\\^2\\], or minimum of 15 mg/week for participants with BSA greater than or equal to \\[\\>=\\] 1.67 m\\^2) as at time of study entry. After Week 28, changes in MTX administration were permitted. Participants who completed Week 52 had the option to enter into the long-term extension (LTE) phase.","id":"EG000","otherNumAffected":74,"otherNumAtRisk":127,"seriousNumAffected":9,"seriousNumAtRisk":127,"title":"Treatment Period (Week 0 to 52): Golimumab 80 mg/m^2 IV q8w"},{"deathsNumAffected":1,"deathsNumAtRisk":127,"description":"Participants who completed Week 52 and entered into the LTE phase, continued to receive 80 mg/m\\^2 intravenous golimumab every 8 weeks through Week 244. Those who chose not to enter LTE completed an additional 8-week safety follow-up visit after their final administration of the study agent. All participants who completed Week 244 were monitored for safety through Week 252.","id":"EG001","otherNumAffected":57,"otherNumAtRisk":127,"seriousNumAffected":18,"seriousNumAtRisk":127,"title":"LTE Period (Week 52 to 252): Golimumab 80 mg/m^2 IV q8w"},{"deathsNumAffected":0,"deathsNumAtRisk":32,"description":"Participants who met the inclusion criteria entered the ETP and continued receiving 80 mg/m\\^2 intravenous golimumab every 8 weeks from Week 252 to Week 420.","id":"EG002","otherNumAffected":8,"otherNumAtRisk":32,"seriousNumAffected":3,"seriousNumAtRisk":32,"title":"ETP (Week 252 to 420): Golimumab 80 mg/m^2 IV q8w"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Abdominal Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Nausea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Vomiting"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":127},{"groupId":"EG001","numAffected":12,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Gastroenteritis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":127},{"groupId":"EG001","numAffected":16,"numAtRisk":127},{"groupId":"EG002","numAffected":2,"numAtRisk":32}],"term":"Nasopharyngitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Pharyngitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":127},{"groupId":"EG001","numAffected":19,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Upper Respiratory Tract Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":12,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Urinary Tract Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Alanine Aminotransferase Increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 27.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":127},{"groupId":"EG002","numAffected":3,"numAtRisk":32}],"term":"Arthritis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":18,"numAtRisk":127},{"groupId":"EG002","numAffected":2,"numAtRisk":32}],"term":"Juvenile Idiopathic Arthritis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":6,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Headache"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Myopericarditis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Supraventricular Tachycardia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Glaucoma"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Retinal Detachment"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Constipation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Crohn's Disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Gastritis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Calcinosis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Drug Intolerance"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Ocular Implant Exposure"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Temperature Regulation Disorder"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Hypersensitivity"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":1,"numAtRisk":32}],"term":"Appendicitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Cellulitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Disseminated Tuberculosis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Escherichia Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Furuncle"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Herpes Zoster Disseminated"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Infective Exacerbation of Bronchiectasis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Pneumonia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Pneumonia Streptococcal"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Sepsis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Septic Shock"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Tonsillitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Varicella"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Clavicle Fracture"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Systemic Lupus Erythematosus"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Cutaneous T-Cell Lymphoma"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Generalised Anxiety Disorder"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Major Depression"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Suicidal Ideation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Hydronephrosis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Pleural Effusion"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 21.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":127},{"groupId":"EG002","numAffected":0,"numAtRisk":32}],"term":"Cyanosis"}],"timeFrame":"Treatment Period Arm: All cause mortality (From screening [-6 weeks] up to Week 52), Serious and Other AEs (Week 0 up to Week 52); LTE Period Arm: Week 52 up to Week 252; ETP Arm: Week 252 up to Week 420"}